Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
Catalyst Pharmaceuticals (Nasdaq: CPRX) has announced that it will release its third quarter 2024 financial results after the market close on Wednesday, November 6, 2024. The company's management team will host a conference call and webcast on Thursday, November 7, 2024, at 8:30 AM ET to discuss the financial results and provide a business update.
Interested parties can access the conference call via the following dial-in numbers:
- US/Canada: 800-715-9871
- International: 646-307-1963
Catalyst Pharmaceuticals (Nasdaq: CPRX) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato il mercoledì 6 novembre 2024. Il team di gestione dell'azienda ospiterà una chiamata e una webcast il giovedì 7 novembre 2024, alle 8:30 ET per discutere dei risultati finanziari e fornire un aggiornamento sull'attività.
Le parti interessate possono accedere alla chiamata tramite i seguenti numeri da comporre:
- US/Canada: 800-715-9871
- Internazionale: 646-307-1963
Catalyst Pharmaceuticals (Nasdaq: CPRX) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el miércoles 6 de noviembre de 2024. El equipo de gestión de la empresa llevará a cabo una llamada y un webcast el jueves 7 de noviembre de 2024, a las 8:30 AM ET para discutir los resultados financieros y proporcionar una actualización comercial.
Los interesados pueden acceder a la llamada a través de los siguientes números de acceso:
- EE.UU./Canadá: 800-715-9871
- Internacional: 646-307-1963
Catalyst Pharmaceuticals (Nasdaq: CPRX)는 2024년 3분기 재무 결과를 2024년 11월 6일 수요일 시장 마감 후 발표할 것이라고 발표했습니다. 회사의 관리 팀은 2024년 11월 7일 목요일 오전 8:30 ET에 재무 결과에 대해 논의하고 사업 업데이트를 제공하기 위해 전화 회의 및 웹캐스트를 개최합니다.
관심 있는 모든 분들은 다음 번호로 전화 회의에 접속할 수 있습니다:
- 미국/캐나다: 800-715-9871
- 국제: 646-307-1963
Catalyst Pharmaceuticals (Nasdaq: CPRX) a annoncé qu'il publiera ses résultats financiers du troisième trimestre 2024 après la fermeture du marché le mercredi 6 novembre 2024. L'équipe de direction de la société animera une conférence téléphonique et un webcast le jeudi 7 novembre 2024, à 8h30 ET pour discuter des résultats financiers et fournir une mise à jour sur l'activité.
Les parties intéressées peuvent accéder à la conférence téléphonique via les numéros suivants :
- États-Unis/Canada : 800-715-9871
- International : 646-307-1963
Catalyst Pharmaceuticals (Nasdaq: CPRX) hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 nach Börsenschluss am Mittwoch, den 6. November 2024 veröffentlichen wird. Das Management-Team des Unternehmens wird am Donnerstag, den 7. November 2024, um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse zu erörtern und ein Update zum Geschäft zu geben.
Interessierte Parteien können auf die Telefonkonferenz über die folgenden Einwahlnummern zugreifen:
- USA/Kanada: 800-715-9871
- International: 646-307-1963
- None.
- None.
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET
CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2024 financial results after the market close on Wednesday, November 6, 2024.
Catalyst's management team will host a conference call and webcast on Thursday, November 7, 2024, at 8:30 AM ET to discuss the Company's financial results and provide a business update.
Conference Call & Webcast Details | |
Date: | November 7, 2024 |
Time: | 8:30 AM ET |
US/Canada Dial-in Number: | 800-715-9871 |
International Dial-in Number: | 646-307-1963 |
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on the Catalyst website for at least 30 days following the date of the event.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When will Catalyst Pharmaceuticals (CPRX) release its Q3 2024 financial results?
What is the date and time of Catalyst Pharmaceuticals' (CPRX) Q3 2024 earnings call?
How can I access Catalyst Pharmaceuticals' (CPRX) Q3 2024 earnings call?